Improving access to life-changing treatment for sickle cell patients in Saudi Arabia

As part of our long-term strategic partnership with Theravia, we have successfully expanded Siklos® into Saudi Arabia. This case study highlights how careful market preparation, KOL engagement, and national account management can accelerate access to essential treatments in a new territory.

Improving access to treatments for sickle cell patients in Saudi Arabia

Expanding access to innovative treatments for sickle cell disease (SCD) requires long-term commitment, local expertise, and strong strategic partnerships. As part of our ongoing collaboration with Theravia, we are expanding territories for Siklos® in Saudi Arabia, reinforcing a shared vision to improve outcomes for patients living with SCD across the region.

‍

Navigating the local regulatory pathway

A critical first step in expanding access was successfully navigating the local licensing process with the Saudi Food and Drug Authority (SFDA). Registering Siklos® in Saudi Arabia required close coordination, detailed regulatory expertise, and alignment with national requirements to ensure timely approval and compliance. This foundational work enabled a structured and sustainable market entry.

‍

Strong national account management and distribution

To ensure effective reach and supply continuity, we partnered with a trusted in-country commercial and distribution partner. Through dedicated national key account management, we established relationships with major treatment centres, hospitals, and healthcare stakeholders across the Kingdom. This approach ensures reliable product availability while supporting healthcare professionals with the information and service they need.

‍

A robust pre-launch medical strategy

Ahead of launch, a comprehensive medical marketing strategy was implemented. This included in-depth disease and target mapping to understand patient populations, treatment pathways, and key centres of excellence. Collaboration with leading KOLs helped build advocacy and clinical confidence, while fully aligned marketing activities ensured consistency of messaging and clear communication of Siklos®’s value within the local healthcare landscape.

‍

Sustained post-launch growth

Following launch, a focused sales and marketing strategy was deployed to drive uptake and maintain momentum. Ongoing engagement with healthcare professionals, continued educational initiatives, and close alignment between commercial and medical teams have supported sustained growth and strengthened Siklos®’s position in the Saudi market.

‍

A long-term commitment to patient access

This expansion represents more than a product launch—it reflects a long-term strategic partnership with Theravia dedicated to improving access to treatment for sickle cell patients in Saudi Arabia. By combining regulatory expertise, strong local partnerships, and a carefully phased commercial strategy, we are helping ensure that more patients can benefit from appropriate and timely care.

‍

Read Next

Collaboration that improves treatment options for sickle cell patients in the UK

In exclusive partnership with Theravia, we are driving sustainable growth and improving nationwide access to Siklos® across the UK. Through targeted national key account management, deep NHS and haematology network expertise, and strong KOL advocacy, we are supporting specialist centres and strengthening treatment pathways for patients living with sickle cell disease. This case study explores how a focused commercial strategy, combined with disease insight and stakeholder engagement, is expanding access and delivering measurable impact in a complex healthcare environment.

Commercialisation of Desferal® in Brazil, in partnership with Mitem Pharma

In partnership with Mitem Pharma, we are strengthening access to essential haematology treatments across Brazil. The successful transfer of Desferal® from Novartis, combined with a dedicated haematology sales force and a locally tailored commercial strategy, has reinforced our growing portfolio in the region.